From Name:
From Email:
To Name:
To Email:

Optional Message:

BMS' Opdivo evens the score in melanoma with 2 new FDA green lights

from FiercePharma

Thanks to an FDA decision over the weekend, Bristol-Myers Squibb's immunotherapy Opdivo has caught back up to Merck's Keytruda in melanoma. And it won a new combination approval from the FDA to boot. Last fall, the FDA handed Keytruda a lead in advanced melanoma, approving the Merck drug for previously untreated patients regardless of the genetic characteristics of their tumors. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063